Enzymotec yesterday announced that it has received US approval for its proprietary enzymatic technology for producing Lyso-phospholipids.
This announcement follows a recent announcement of the launch of the SharpPS goldTM , a conjugated system of PS and DHA and the previous announcements of the development of novel delivery systems, based on certain phospholipid carriers.
Lyso-phospholpids are obtained from lecithin, which passes through an enzymatic process. This environment-friendly process enables the specific detachment of certain fatty acids from the phospholipid backbone.
"These compounds are important carriers of essential fatty acids and are widley used in various industries as important emulsifiers" said Enzymotec spokesman.
"For Enzymotec, they are mainly used as intermediates for processing advanced lipids, capable of boosting the bioavailability of essential fats and thus improve cognitive condition, reduce CVD risks, etc.." concludes this source.
Enzymotec is an Israeli biotech company, developing bio-functional nutraceuticals among which are: SharpPSTM for improving cognitive performance in the elderly, InFatTM for balanced nutrition in infant formulas and CardiaBeatTM for reducing CVD risks.